A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2018
At a glance
- Drugs MGD 013 (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors MacroGenics
- 27 Feb 2018 According to a MacroGenics media release, the company expects to establish the dose and schedule for MGD013 administration as well as initiate dose expansion cohorts in 2018.
- 10 Nov 2017 According to a MacroGenics media release, results from this trial will be presented at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
- 05 Sep 2017 According to a MacroGenics media release, the first patient has been dosed in this trial.